EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk

David Damoiseaux iD, Frédéric Amant, Jos H Beijnen, Shelby Barnett, Gareth J Veal iD, Alwin D R Huitema, Thomas P C Dorlo iD

CPT: Pharmacometrics & Systems Pharmacology · 2023-12 · 12 (12) · 1931-1944

DOI: 10.1002/psp4.13043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.10.2023. Verfasst von David Damoiseaux und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Milk, Human, Paclitaxel. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited information is available concerning infant exposure and safety when breastfed by mothers receiving chemotherapy. Whereas defining distribution to breast milk is important to infer drug exposure, infant pharmacokinetics also determine to what extent the infant will be exposed to potential toxic effects. We aimed to assess the impact of chemotherapy containing breast milk on infants by predicting systemic and local (intestinal) exposure of paclitaxel and doxorubicin in infants through breast milk using a physiologically‐based pharmacokinetic (PBPK) approach. Whole‐body PBPK models of i.v. paclitaxel and doxorubicin were extended from the literature, with an oral absorption component to enable predictions in infants receiving paclitaxel or doxorubicin‐containing breast milk. For safety considerations, worst‐case scenarios were explored. Finally, paclitaxel and doxorubicin exposures in plasma and intestinal tissue of infants following feeding of breast milk from paclitaxel‐ or doxorubicin‐treated mothers were simulated and breast milk discarding strategies were evaluated. The upper 95th percentile of the predicted peak concentrations in peripheral venous blood were 3.48 and 0.74 nM (0.4%–1.7% and 0.1%–1.8% of on‐treatment) for paclitaxel and doxorubicin, respectively. Intestinal exposure reached peak concentrations of 1.0 and 140 μM for paclitaxel and doxorubicin, respectively. Discarding breast milk for the first 3 days after maternal chemotherapy administration reduced systemic and tissue exposures even further, to over 90% and 80% for paclitaxel and doxorubicin, respectively. PBPK simulations of chemotherapy exposure in infants after breastfeeding with chemotherapy containing breast milk suggest that particularly local gastrointestinal adverse events should be monitored, whereas systemic adverse events are not expected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Milk, HumanPaclitaxelInfantFemaleHumansBreast FeedingDoxorubicinMothers

Substanzen

PaclitaxelDoxorubicin

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Gynecologic Oncology, UZ Leuven, Leuven, Belgium.
  • Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
  • Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

ORCID-Profile: David Damoiseaux, Gareth J Veal, Thomas P C Dorlo

Zitieren

APA

Damoiseaux, D., Amant, F., Beijnen, J. H., Barnett, S., Veal, G. J., Huitema, A. D. R., & Dorlo, T. P. C. (2023). Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT: Pharmacometrics & Systems Pharmacology, 12(12), 1931-1944. https://doi.org/10.1002/psp4.13043

Vancouver

Damoiseaux D, Amant F, Beijnen JH, Barnett S, Veal GJ, Huitema ADR, et al. Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT: Pharmacometrics & Systems Pharmacology. 2023;12(12):1931-1944. doi:10.1002/psp4.13043

BibTeX
@article{Damoiseaux2023,
  author = {Damoiseaux, David and Amant, Frédéric and Beijnen, Jos H and Barnett, Shelby and Veal, Gareth J and Huitema, Alwin D R and Dorlo, Thomas P C},
  title = {Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {1931--1944},
  doi = {10.1002/psp4.13043}
}
Kostenlos starten →